|1.||Carr, Brian I: 14 articles (12/2007 - 01/2002)|
|2.||Wang, Meifang: 11 articles (12/2007 - 01/2002)|
|3.||Wang, Ziqiu: 8 articles (12/2007 - 01/2002)|
|4.||Carr, B I: 6 articles (12/2008 - 03/2000)|
|5.||Kar, Siddhartha: 6 articles (11/2006 - 08/2002)|
|6.||Osada, S: 3 articles (12/2001 - 12/2000)|
|7.||Kar, S: 2 articles (12/2008 - 12/2000)|
|8.||Ge, Lisheng: 2 articles (12/2007 - 07/2006)|
|9.||Ham, Seung Wook: 2 articles (11/2006 - 10/2006)|
|10.||Zhang, Baochun: 2 articles (08/2005 - 03/2003)|
|1.||Hepatocellular Carcinoma (Hepatoma)
07/01/2006 - "To study the relationship between ERK phosphorylation and cell growth inhibition, we used Cpd 5 as a tool to investigate ERK-regulated c-Myc expression in Hep3B hepatoma cells. "
09/01/2005 - "Therefore, we investigated the effect of Cpd 5 in human hepatocellular carcinoma (HCC) cell lines and evaluated its role in apoptosis. "
08/01/2005 - "Transfection of Hep3B human hepatoma cells with inactive Cdc25A mutant enhanced Cpd 5 action on ERK phosphorylation, whereas over-expression of Cdc25A attenuated this Cpd 5 action. "
12/01/2002 - "Cpd 5 could also inhibit both normal liver regeneration and hepatoma growth in vivo. "
11/15/2006 - "Fluorinated Cpd 5, a pure arylating K-vitamin derivative, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating MAPK."
|2.||Pancreatic Neoplasms (Pancreatic Cancer)
|3.||Renal Cell Carcinoma (Grawitz Tumor)
06/01/2005 - "In contrast, HGF antagonized the growth inhibitory actions of Cpd 5 on normal rat hepatocytes, thus showing a selective effect on tumor cells compared to normal cells. "
11/15/2006 - "F-Cpd 5 thus differentially inhibited growth of normal and tumor cells by preferentially inhibiting the actions of Cdc25A and Cdc25B phosphatases and inducing MAPK phosphorylation."
09/01/2005 - "A systemic vitamin K analog, compound 5 (Cpd 5), possesses the ability to inhibit cell growth of tumor cells. "
03/01/2003 - "As in JM-1 cells in vitro, ERK1/2 was phosphorylated when rats in vivo were treated with Cpd 5 and tumor growth inhibition in vivo also was antagonized by treating rats with the ERK1/2 phosphorylation inhibitor PD098059. "
12/07/2001 - "Here, we show that CPD-5 and two newly synthesized analogs, 2-(2-hydroxy-ethylsulfanyl)-3-methyl-5- nitro-1,4-naphthoquinone (PD-37) and 2-(2-hydroxy-ethylsulfanyl)-3- methyl-5-acetylamino-1,4-naphthoquinone (PD-42), are potent growth inhibitors of 13 different human cancer cell lines, with IC50 values in the range of 3-54 microM. "
|5.||Kidney Neoplasms (Kidney Cancer)
09/01/2005 - "Cpd 5 showed a strong cytotoxicity against all renal cancer cell lines with an apoptosis-inducing effect. "
09/01/2005 - "The effects of Cpd 5 on the viability of renal cancer cell lines was analyzed using an Alamar Blue assay. "
09/01/2005 - "In organ cultures from RCCs, TUNEL-positive apoptotic nuclei were observed when treated with Cpd 5. Cpd 5 was thus found to effectively inhibit the proliferation of human renal cancer cells while also inducing apoptosis by inhibiting cdc25 phosphatases and modulating bcl-2 family proteins. "
09/01/2005 - "Modulation of bcl-2 family proteins in MAPK independent apoptosis induced by a cdc25 phosphatase inhibitor Cpd 5 in renal cancer cells."
|1.||Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)
|2.||Transcription Factors (Transcription Factor)
|3.||2- (2- hydroxyethylsulfaryl)- 3- methyl- 1,4- naphthoquinone
|7.||DNA (Deoxyribonucleic Acid)
|9.||Protein Tyrosine Phosphatases
|10.||Epidermal Growth Factor Receptor (EGF Receptor)